NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.82
−5.26%Research · Aug 25, 2026
Rare-Disease Gene Therapy Shifts From Sham-Surgery Control to Delivery Hardware and Endpoint Instruments
The FDA told uniQure a sham-surgery control is no longer required, moving the cost of rare-disease gene therapy onto delivery hardware and endpoint instruments.